News

April 15, 2021April 15, 2021

Safety Seen in Trial of Oral Treatment, Anavex 2-73, for Early Alzheimer’s

News

Following a positive review of preliminary data, an independent board recommended the Phase 2b/3 study investigating oral Anavex 2-73 (blarcamesine) in people with early Alzheimer’s disease continue without modification. As specified in trial ... Read more

April 12, 2021April 12, 2021

GV1001 Treatment Shows Promise for Moderate to Severe Alzheimer’s

News

Six months of treatment with GemVax & KAEL’s investigational GV1001 provided benefits in the cognition and daily life activities of adults with moderate to severe Alzheimer’s disease, who take Aricept ... Read more

April 8, 2021April 8, 2021

Effects of War, Dementia Animated in Short Film ‘Winter Memories’

News

Zahra Kababian had a special bond with her father, and even though he died suddenly 10 years ago, it’s the memories they shared that keeps him alive in her heart. ... Read more

April 5, 2021April 5, 2021

FDA Rejects Nuplazid to Treat Dementia-related Psychosis

News

The U.S. Food and Drug Administration (FDA) has rejected Acadia Pharmaceuticals’ request that Nuplazid (pimavanserin) be the first approved treatment of hallucinations and delusions associated with dementia-related psychosis. The decision comes less than ... Read more

April 1, 2021April 1, 2021

Montana Residents May Order Free Children’s Storybook About Alzheimer’s

News

Montana residents who wish to help their children or young relatives better understand Alzheimer’s disease can now access a free storybook and reading guide. The reading guide, offered by the ... Read more

March 29, 2021March 29, 2021

Sargramostim, Immune System Activator, May Aid Cognition, Small Trial Finds

News

People with mild-to-moderate Alzheimer’s disease treated for three weeks with sargramostim, a medication that activates the immune system, showed improvements in cognition in a small clinical trial. These results support further ... Read more

March 26, 2021March 25, 2021

Donanemab Shows Potential for Early Alzheimer’s in Phase 2 Trial

News

Donanemab showed an ability to slow cognitive decline and the loss of daily life abilities in people at earlier stages of Alzheimer’s disease relative to those given a placebo in the Phase ... Read more

March 22, 2021March 22, 2021

Sulbutamol, for Respiratory Ills, Seen to Improve Blood Flow in Brain

News

Use of salbutamol significantly improved blood flow — a measure of cerebral perfusion, or the steady flow of nutrients and oxygen via the blood to brain tissue — in healthy ... Read more

March 18, 2021March 18, 2021

Neurostimulation Slows Decline in Mild-to-moderate Alzheimer’s, Trial Finds

News

Non-invasive neurostimulation given to people with mild-to-moderate Alzheimer’s disease significantly and safely slowed their rate of functional and cognitive decline, meeting key goals of the Phase 2 OVERTURE study, according to data ... Read more

March 15, 2021March 15, 2021

Noninvasive Genetic Risk Test for Alzheimer’s Coming to EU, US

News

Cytox has launched a noninvasive genetic test, called genoSCORE-LAB, that can help to predict a person’s risk of developing Alzheimer’s disease and the cognitive decline it brings. Early detection of possible risk ... Read more